IT1177152B - Procedimento e composizione per la preparazione di prodotti farmaceutici ad azione prolungata controllata per la somministrazione orale - Google Patents

Procedimento e composizione per la preparazione di prodotti farmaceutici ad azione prolungata controllata per la somministrazione orale

Info

Publication number
IT1177152B
IT1177152B IT23523/84A IT2352384A IT1177152B IT 1177152 B IT1177152 B IT 1177152B IT 23523/84 A IT23523/84 A IT 23523/84A IT 2352384 A IT2352384 A IT 2352384A IT 1177152 B IT1177152 B IT 1177152B
Authority
IT
Italy
Prior art keywords
procedure
preparation
composition
oral administration
pharmaceutical products
Prior art date
Application number
IT23523/84A
Other languages
English (en)
Other versions
IT8423523A1 (it
IT8423523A0 (it
Inventor
Hans Lowey
Original Assignee
Hans Lowey
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Hans Lowey filed Critical Hans Lowey
Publication of IT8423523A0 publication Critical patent/IT8423523A0/it
Publication of IT8423523A1 publication Critical patent/IT8423523A1/it
Application granted granted Critical
Publication of IT1177152B publication Critical patent/IT1177152B/it

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/02—Suppositories; Bougies; Bases therefor; Ovules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/0056—Mouth soluble or dispersible forms; Suckable, eatable, chewable coherent forms; Forms rapidly disintegrating in the mouth; Lozenges; Lollipops; Bite capsules; Baked products; Baits or other oral forms for animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/0012—Galenical forms characterised by the site of application
    • A61K9/0053—Mouth and digestive tract, i.e. intraoral and peroral administration
    • A61K9/006—Oral mucosa, e.g. mucoadhesive forms, sublingual droplets; Buccal patches or films; Buccal sprays
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/2027—Organic macromolecular compounds obtained by reactions only involving carbon-to-carbon unsaturated bonds, e.g. polyvinyl pyrrolidone, poly(meth)acrylates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/20—Pills, tablets, discs, rods
    • A61K9/2004—Excipients; Inactive ingredients
    • A61K9/2022—Organic macromolecular compounds
    • A61K9/205—Polysaccharides, e.g. alginate, gums; Cyclodextrin
    • A61K9/2054—Cellulose; Cellulose derivatives, e.g. hydroxypropyl methylcellulose

Landscapes

  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Chemical & Material Sciences (AREA)
  • Nutrition Science (AREA)
  • Physiology (AREA)
  • Zoology (AREA)
  • Medicinal Preparation (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
IT23523/84A 1983-12-01 1984-11-09 Procedimento e composizione per la preparazione di prodotti farmaceutici ad azione prolungata controllata per la somministrazione orale IT1177152B (it)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US06/556,844 US4680323A (en) 1983-12-01 1983-12-01 Method and composition for the preparation of controlled long-acting pharmaceuticals for oral administration

Publications (3)

Publication Number Publication Date
IT8423523A0 IT8423523A0 (it) 1984-11-09
IT8423523A1 IT8423523A1 (it) 1986-05-09
IT1177152B true IT1177152B (it) 1987-08-26

Family

ID=24223083

Family Applications (1)

Application Number Title Priority Date Filing Date
IT23523/84A IT1177152B (it) 1983-12-01 1984-11-09 Procedimento e composizione per la preparazione di prodotti farmaceutici ad azione prolungata controllata per la somministrazione orale

Country Status (26)

Country Link
US (1) US4680323A (it)
JP (1) JPS60185728A (it)
KR (1) KR930000046B1 (it)
AT (1) AT394948B (it)
AU (1) AU572571B2 (it)
BE (1) BE901186A (it)
CA (1) CA1229551A (it)
CH (1) CH664970A5 (it)
DE (1) DE3443587C2 (it)
DK (1) DK162511C (it)
EG (1) EG17134A (it)
FI (1) FI82601C (it)
FR (1) FR2555901B1 (it)
GB (1) GB2152940B (it)
HU (1) HU193717B (it)
IE (1) IE58112B1 (it)
IL (1) IL73594A (it)
IT (1) IT1177152B (it)
LU (1) LU85660A1 (it)
MX (1) MX161165A (it)
NL (1) NL193164C (it)
NO (1) NO167002C (it)
NZ (1) NZ210310A (it)
PT (1) PT79427B (it)
SE (1) SE461071B (it)
ZA (1) ZA849373B (it)

Families Citing this family (68)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DK62184D0 (da) * 1984-02-10 1984-02-10 Benzon As Alfred Diffusionsovertrukket polydepotpraeparat
IE59287B1 (en) * 1984-02-10 1994-02-09 Benzon Pharma As Diffusion coated multiple-units dosage form
JPS6185315A (ja) * 1984-10-04 1986-04-30 Teikoku Seiyaku Kk シ−ト状製剤
EP0205336B1 (en) * 1985-06-11 1991-09-11 Teijin Limited Oral sustained release pharmaceutical preparation
JPS61286330A (ja) * 1985-06-11 1986-12-16 Teijin Ltd 経口徐放性製剤
GB8518927D0 (en) * 1985-07-26 1985-09-04 Vincent Processes Ltd Tablets
US4704285A (en) * 1985-11-18 1987-11-03 The Dow Chemical Company Sustained release compositions comprising hydroxypropyl cellulose ethers
JPS62120315A (ja) * 1985-11-20 1987-06-01 Shin Etsu Chem Co Ltd 経口投与型徐放性錠剤の製造方法
ZA881301B (en) * 1987-02-27 1989-10-25 Lilly Co Eli Sustained release matrix formulations
US4783331A (en) * 1987-06-29 1988-11-08 Miles Inc. Method for solubilization of aspartame in effervescent aqueous systems; and composition
AU2252388A (en) * 1988-05-02 1989-11-29 Zila Pharmaceuticals Compositions and in situ methods for forming films on body tissue
US5612059A (en) * 1988-08-30 1997-03-18 Pfizer Inc. Use of asymmetric membranes in delivery devices
US5126145A (en) * 1989-04-13 1992-06-30 Upsher Smith Laboratories Inc Controlled release tablet containing water soluble medicament
US5268181A (en) * 1989-04-13 1993-12-07 Upsher-Smith Laboratories, Inc. Method of using niacin to control nocturnal cholesterol synthesis
US5009895A (en) * 1990-02-02 1991-04-23 Merck & Co., Inc. Sustained release with high and low viscosity HPMC
JP2845342B2 (ja) * 1990-04-28 1999-01-13 大正製薬株式会社 ビタミンｄ▲下３▼誘導体含有固形製剤組成物
US5876752A (en) * 1990-08-07 1999-03-02 Pfizer Inc. Use of interfacially-polymerized membranes in delivery devices
US5498422A (en) * 1991-04-08 1996-03-12 Nippon Shinyaku Company Limited Sustained release capsule
US5204116A (en) * 1991-05-01 1993-04-20 Alza Corporation Dosage form providing immediate therapy followed by prolonged therapy
NO924985L (no) * 1991-12-30 1993-07-01 Akzo Nv Thyroaktiv blanding med vedvarende frigjoering
US6080428A (en) 1993-09-20 2000-06-27 Bova; David J. Nicotinic acid compositions for treating hyperlipidemia and related methods therefor
US6818229B1 (en) 1993-09-20 2004-11-16 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia
US6676967B1 (en) 1993-09-20 2004-01-13 Kos Pharmaceuticals, Inc. Methods for reducing flushing in individuals being treated with nicotinic acid for hyperlipidemia
US6746691B2 (en) 1993-09-20 2004-06-08 Kos Pharmaceuticals, Inc. Intermediate release nicotinic acid compositions for treating hyperlipidemia having unique biopharmaceutical characteristics
US6129930A (en) 1993-09-20 2000-10-10 Bova; David J. Methods and sustained release nicotinic acid compositions for treating hyperlipidemia at night
DE4341156C2 (de) * 1993-12-02 1997-11-13 Wacker Chemie Gmbh Verwendung von in Wasser redispergierbaren Kunststoffdispersionspulvern als Arzneimittelträger
US5840756A (en) * 1995-07-21 1998-11-24 Teva Pharmaceutical Industries Ltd. Pharmaceutical composition of L-DOPA ester
DK0906089T3 (da) * 1996-05-13 2003-12-08 Novartis Consumer Health Sa Mundafgivelsessystem
US5948437A (en) * 1996-05-23 1999-09-07 Zeneca Limited Pharmaceutical compositions using thiazepine
US6479082B1 (en) 1996-12-23 2002-11-12 Wm. Wrigley, Jr. Co. Process of increasing flavor release from chewing gum using hydroxypropyl cellulose and product thereof
CA2216215A1 (en) 1997-04-05 1998-10-05 Isa Odidi Controlled release formulations using intelligent polymers having opposing wettability characteristics of hydrophobicity and hydrophilicity
US6210710B1 (en) 1997-04-28 2001-04-03 Hercules Incorporated Sustained release polymer blend for pharmaceutical applications
PL340456A1 (en) * 1997-11-12 2001-02-12 Boehringer Mannheim Pharm Corp Novel oral dosage form of carvedilol
US6207682B1 (en) 1998-12-22 2001-03-27 Novo Nordisk A/S Modified release formulations containing (R)-1-(10,11-dihydro-5H-Dibenzo[a,d]cyclohepten-5-ylidene)-1propyl)-3-piperidinecarboxylic acid
WO2000037081A1 (en) * 1998-12-22 2000-06-29 Novo Nordisk A/S Novel formulation
US6552024B1 (en) 1999-01-21 2003-04-22 Lavipharm Laboratories Inc. Compositions and methods for mucosal delivery
WO2000059314A1 (en) 1999-04-01 2000-10-12 Wm. Wrigley Jr. Company Long flavor duration releasing structures for chewing gum
US7838032B2 (en) * 2000-04-28 2010-11-23 Reckitt Benckiser Inc. Sustained release of guaifenesin
US7985420B2 (en) * 2000-04-28 2011-07-26 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
US6955821B2 (en) * 2000-04-28 2005-10-18 Adams Laboratories, Inc. Sustained release formulations of guaifenesin and additional drug ingredients
US6372252B1 (en) * 2000-04-28 2002-04-16 Adams Laboratories, Inc. Guaifenesin sustained release formulation and tablets
US8012504B2 (en) * 2000-04-28 2011-09-06 Reckitt Benckiser Inc. Sustained release of guaifenesin combination drugs
EP1347748A2 (en) 2000-12-05 2003-10-01 MacGregor, Alexander Hydrostatic delivery system for controlled delivery of agent
US20030044462A1 (en) * 2001-08-20 2003-03-06 Kali Laboratories, Inc. Sustained release tablets containing bupropion hydrochloride
US20030167556A1 (en) * 2002-03-05 2003-09-11 Consumers Choice Systems, Inc. Methods and devices for transdermal delivery of anti-aging compounds for treatment and prevention of facial or neck skin aging
US20060147530A1 (en) * 2002-10-22 2006-07-06 Viswanathan Narayanan B Sustained release compositions containing alfuzosin
US20060074025A1 (en) * 2003-12-26 2006-04-06 Nastech Pharmaceutical Company Inc. Therapeutic formulations for transmucosal administration that increase glucagon-like peptide-1 bioavailability
US20060210614A1 (en) * 2003-12-26 2006-09-21 Nastech Pharmaceutical Company Inc. Method of treatment of a metabolic disease using intranasal administration of exendin peptide
US20080318837A1 (en) * 2003-12-26 2008-12-25 Nastech Pharmaceutical Company Inc. Pharmaceutical Formation For Increased Epithelial Permeability of Glucose-Regulating Peptide
US20050143303A1 (en) * 2003-12-26 2005-06-30 Nastech Pharmaceutical Company Inc. Intranasal administration of glucose-regulating peptides
US20060057165A1 (en) * 2004-09-10 2006-03-16 Dimitrios Dimitrakoudis Clostridium botulinum toxin formulation and method for reducing weight
US20080318311A1 (en) 2004-11-02 2008-12-25 Gangagen Life Sciences Inc. Encapsulated Bacteriophage Formulation
AU2006282506A1 (en) * 2005-08-23 2007-03-01 Nissan Chemical Industries, Ltd. Sustained-release preparation
US20080318861A1 (en) * 2005-12-08 2008-12-25 Nastech Pharmaceutical Company Inc. Mucosal Delivery of Stabilized Formulations of Exendin
US20070185035A1 (en) * 2005-12-23 2007-08-09 Nastech Pharmaceutical Company Inc. Enhanced mucosal administration of neuroprotective peptides
US20090088404A1 (en) * 2007-01-31 2009-04-02 Methylation Sciences International Srl Extended Release Pharmaceutical Formulations of S-Adenosylmethionine
AU2008210327B2 (en) * 2007-01-31 2011-06-16 Methylation Sciences International Srl Extended release pharmaceutical formulations of S-adenosylmethionine
US20090197824A1 (en) * 2008-01-31 2009-08-06 Methylation Sciences International Srl Extended Release Pharmaceutical Formulations of S-Adenosylmethionine
WO2008102235A1 (en) * 2007-02-20 2008-08-28 Aurobindo Pharma Limited Controlled release formulations of alfuzosin
US20090042795A1 (en) * 2007-06-05 2009-02-12 Pasan Fernando Cardiac stem cell proliferation proteins, fragments thereof and methods of modulating stem cell proliferation and differentiation
KR100836960B1 (ko) * 2007-09-07 2008-06-10 주식회사 서울제약 새로운 나이아신 제어방출형 제제
US7928189B2 (en) * 2008-05-05 2011-04-19 Ottawa Health Research Institute PCSK9 polypeptide fragment
WO2009143072A1 (en) * 2008-05-19 2009-11-26 Wynden Pharmaceuticals, Inc. High-loading, controlled-release magnesium oral dosage forms and methods of making and using same
US20110027342A1 (en) * 2009-07-28 2011-02-03 Msi Methylation Sciences, Inc. S-adenosylmethionine formulations with enhanced bioavailability
US8329208B2 (en) 2009-07-28 2012-12-11 Methylation Sciences International Srl Pharmacokinetics of S-adenosylmethionine formulations
WO2016176652A2 (en) 2015-04-29 2016-11-03 Fred Hutchinson Cancer Research Center Modified stem cells and uses thereof
WO2017062997A1 (en) 2015-10-09 2017-04-13 Reckitt Benckiser Llc Pharmaceutical formulation
CN115429815B (zh) * 2021-06-02 2023-12-22 广州帝奇医药技术有限公司 一种长效饱腹组合物、制备方法及用途

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US2887440A (en) * 1957-08-12 1959-05-19 Dow Chemical Co Enteric coating
US3065143A (en) * 1960-04-19 1962-11-20 Richardson Merrell Inc Sustained release tablet
US3138524A (en) * 1962-06-06 1964-06-23 Hoffmann La Roche Pharmaceutical suspensions
US3428728A (en) * 1965-10-21 1969-02-18 Hans Lowey Timed release sublingual medications
GB1171691A (en) * 1967-02-24 1969-11-26 Forest Laboratories Lond-Acting Oral Carrier
US3590117A (en) * 1969-03-24 1971-06-29 Richardson Merrell Inc Long-lasting troche containing guar gum
GB1279214A (en) * 1970-01-22 1972-06-28 Forest Laboratories Long-acting oral carrier
US3870790A (en) * 1970-01-22 1975-03-11 Forest Laboratories Solid pharmaceutical formulations containing hydroxypropyl methyl cellulose
CA945899A (en) * 1971-09-16 1974-04-23 Hans Lowey Long-acting oral carrier
CA1018456A (en) * 1972-06-26 1977-10-04 Hans Lowey Prolonged release lozenges
US3876771A (en) * 1973-09-04 1975-04-08 Hallister Inc Skin protective gel containing polyvinyl methylether or monoisopropyl ester of polyvinyl methylether maleic acid
YU43437B (en) * 1976-05-05 1989-08-31 Lowey Hans Process for obtaining tablets containing an active component with long lasting effect
JPS5562012A (en) * 1978-11-06 1980-05-10 Teijin Ltd Slow-releasing preparation
GB2042888B (en) * 1979-03-05 1983-09-28 Teijin Ltd Preparation for administration to the mucosa of the oral or nasal cavity
JPS55118414A (en) * 1979-03-05 1980-09-11 Teijin Ltd Prolonged release drug and its preparation
US4357469A (en) * 1979-06-14 1982-11-02 Forest Laboratories, Inc. Carrier base material for prolonged release therapeutic compositions
US4226849A (en) * 1979-06-14 1980-10-07 Forest Laboratories Inc. Sustained release therapeutic compositions
CA1146866A (en) * 1979-07-05 1983-05-24 Yamanouchi Pharmaceutical Co. Ltd. Process for the production of sustained release pharmaceutical composition of solid medical material
US4259314A (en) * 1979-12-10 1981-03-31 Hans Lowey Method and composition for the preparation of controlled long-acting pharmaceuticals
US4369172A (en) * 1981-12-18 1983-01-18 Forest Laboratories Inc. Prolonged release therapeutic compositions based on hydroxypropylmethylcellulose
US4389393A (en) * 1982-03-26 1983-06-21 Forest Laboratories, Inc. Sustained release therapeutic compositions based on high molecular weight hydroxypropylmethylcellulose
JPS58192817A (ja) * 1982-05-06 1983-11-10 Nippon Soda Co Ltd 棒状製剤の製造方法
CA1208558A (en) * 1982-10-07 1986-07-29 Kazuo Kigasawa Soft buccal
US4540566A (en) * 1984-04-02 1985-09-10 Forest Laboratories, Inc. Prolonged release drug dosage forms based on modified low viscosity grade hydroxypropylmethylcellulose

Also Published As

Publication number Publication date
IL73594A (en) 1988-12-30
SE8406081L (sv) 1985-06-02
US4680323A (en) 1987-07-14
FI82601C (fi) 1991-04-10
IL73594A0 (en) 1985-02-28
BE901186A (fr) 1985-03-15
DK569784A (da) 1985-06-02
HU193717B (en) 1987-11-30
GB2152940B (en) 1987-09-03
DE3443587C2 (de) 1986-11-06
PT79427A (en) 1984-11-01
LU85660A1 (de) 1985-06-04
IE843077L (en) 1985-06-01
KR930000046B1 (ko) 1993-01-06
NL8403522A (nl) 1985-07-01
MX161165A (es) 1990-08-09
DE3443587A1 (de) 1985-06-27
NL193164B (nl) 1998-09-01
PT79427B (en) 1986-09-15
DK162511B (da) 1991-11-11
NO844280L (no) 1985-06-03
NO167002C (no) 1991-09-25
HUT35531A (en) 1985-07-29
AT394948B (de) 1992-07-27
CA1229551A (en) 1987-11-24
KR850004392A (ko) 1985-07-15
AU3449984A (en) 1985-06-06
IT8423523A1 (it) 1986-05-09
DK569784D0 (da) 1984-11-30
GB8430083D0 (en) 1985-01-09
GB2152940A (en) 1985-08-14
ATA382484A (de) 1992-01-15
DK162511C (da) 1992-03-30
FI844656L (fi) 1985-06-02
NZ210310A (en) 1988-01-08
FI82601B (fi) 1990-12-31
IT8423523A0 (it) 1984-11-09
CH664970A5 (de) 1988-04-15
SE461071B (sv) 1990-01-08
NL193164C (nl) 1999-01-05
NO167002B (no) 1991-06-17
SE8406081D0 (sv) 1984-11-30
ZA849373B (en) 1985-07-31
FR2555901A1 (fr) 1985-06-07
AU572571B2 (en) 1988-05-12
EG17134A (en) 1991-08-30
FR2555901B1 (fr) 1988-06-10
JPS60185728A (ja) 1985-09-21
IE58112B1 (en) 1993-07-14
FI844656A0 (fi) 1984-11-27

Similar Documents

Publication Publication Date Title
IT1177152B (it) Procedimento e composizione per la preparazione di prodotti farmaceutici ad azione prolungata controllata per la somministrazione orale
IT1184653B (it) Preparato a forma di foglio per la somministrazione di prodotti nella cavita' orale
IT8467445A1 (it) Composizione e preparato per la somministrazione di medicamenti per via cutanea.
IT1178193B (it) Perfezionamento nelle capsule divisibili per la somministrazione dosata di prodotti farmaceutici
IT1190929B (it) Diidropiridine dotate di azione inotropa positiva,composti,loro impiego in prodotti medicinali e procedimento per la loro preparazione
NO871791L (no) Fremgangsmaate for fremstilling av farmasoeytiske preparater inneholdende syrelabile stoffer for oral anvendelse.
IT1173705B (it) Formulazione farmaceutica di clometacina per somministrazione orale e procedimento di preparazione
IT8248908A0 (it) Composizione farmaceutica per la somministrazione per via orale dicomposti che debbono essere assorbiti nell'intestino crasso
AU1578688A (en) Pharmaceutical composition, for oral administration, designed to attenuate the effects of beta-lactamines
ITMI921930A1 (it) Composizioni farmaceutiche per la somministrazione orale di diidropiridine in forma di bevanda
IT8220758A0 (it) Prodotti farmaceutici informa-ritardo e procedimento per ottenerli.
IT1149052B (it) Formulazione granulare mista ad azione prolungata, in particolare per la somministrazione orale di antibiotici
IT8419950A0 (it) Contengono i prodotti emichetali di (8s)-8-fluoroeritromi cine, il procedimento per la loro preparazione e le formulazioni adatte alla somministrazione orale che
IT8424159A0 (it) Composizioni farmaceutiche antitumorali e procedimento per laloro preparazione.
IL84344A0 (en) Pharmaceutical compositions comprising ibuprofen and tizanidine or salts thereof and their preparation
IT8219012A0 (it) Metodo per la somministrazione orale di sostanze sotto forma di liposomi, e relative formulazioni farmaceutiche.
IT9021021A0 (it) Composizioni farmaceutiche per la somministrazione orale di irudina
EG18213A (en) Pharmaceutical formulation for the treatment of bacterial infections
ZA849442B (en) Sphingosine derivatives,their preparation and pharmaceutical formulation
IL81926A0 (en) Pharmaceutical compositions for the oral administration of active proteins
IT1170255B (it) Composizione farmaceutica per la somministrazione orale di calcitonina
IT8421648A1 (it) Nuove difluoroepossidoeritromicine, il procedimento per la loro preparazione e le formulazioni adatte alla somministrazione orale che contengono i nuovi prodotti
ITPD920141A0 (it) Formulazione farmaceutiche per la somministraziane orale di calcitoni-na
IT8919574A0 (it) Procedimento ed impianto per la preparazione di prodotti farmaceutici in genere.
MX9203614A (es) Formulacion farmaceutica de liberacion controlada para administracion oral.

Legal Events

Date Code Title Description
TA Fee payment date (situation as of event date), data collected since 19931001

Effective date: 19971125